ESC 2019 – Novartis sees reasons to push on post-Paragon
With a narrow primary endpoint miss and a 15% decrease in hospitalisations, Novartis is adamant that Entresto can get approved in HFpEF.
Upcoming events – pivotal tests approach for Lilly and Biohaven
Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
Upcoming events – Roche and Novartis hope to push forward again in melanoma
Adding immunotherapy to targeted drugs could improve responses in some metastatic melanomas. Two pending pivotal trials will show whether the increased toxicity is worth…
Astra could use a voucher to cement roxadustat’s head start
Spending $95m to speed up the anaemia project’s path to approval could be worth the investment for Astrazeneca.
ESC preview – Medicines Company hopes for a starring role
Novartis has been reduced to a Paragon data dredge, but results with The Medicines Company’s inclisiran, Astrazeneca’s Brilinta and Cellaegis’ AutoRIC device should pique…
Warning signs were always there for Novartis’s Avexis deal
High-profile departures at Avexis raise more questions about Novartis’s acquisition, but there were plenty of red flags before the deal was sealed.
Novartis cast-off gives Pharming a gap-filler
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
What Enbrel needs to do after its patent win
A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
Autolus slams on the brakes in its Car
Blaming manufacturing delays and competitive pressure, Autolus asks investors to reset expectations.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.